By Lisa Kerner
Charlotte, N.C., June 12 - TetraLogic Pharmaceuticals said it completed a $36 million round of series B private equity financing.
Proceeds from the financing will be used to advance the company's Inhibitor of Apoptosis Proteins antagonist oncology program through initial clinical trials, according to a news release.
The financing was led by Latterell Venture Partners, joined by new investors Quaker BioVentures, The Vertical Group and Amgen Ventures and TetraLogic's existing investors HealthCare Ventures, PA Early Stage Partners and Kammerer Associates.
Larry A. Lasky of Latterell Venture Partners, Brenda D. Gavin of Quaker BioVentures and Jack W. Lasersohn of The Vertical Group will join TetraLogic's board of directors.
Located in Malvern, Pa., TetraLogic is a privately held company focused on discovering and developing new oncology drugs.
| Issuer: | TetraLogic Pharmaceuticals
|
| Issue: | Series B financing
|
| Amount: | $36 million
|
| Investors: | Latterell Venture Partners (lead), Quaker BioVentures, The Vertical Group, Amgen Ventures, HealthCare Ventures, PA Early Stage Partners, Kammerer Associates.
|
| Announcement date: | June 12
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
